Isomorphic Labs announced a research collaboration with MSD on November 19, 2026, to pursue small-molecule candidates for an oncology target. The company announced the partnership; STAT reported that the target’s identity has not been disclosed. MSD is the name Merck & Co., Inc. uses outside the United States and Canada.
What the collaboration is designed to do
The work is at the drug-discovery stage. Isomorphic Labs is to use its IsoDDE engine to generate computational predictions and molecular designs. MSD is to contribute selected proprietary datasets. MarketScreener reported these parts of the arrangement; the program’s target is one oncology target.
The key handoff is from computational design to pharmaceutical development: Isomorphic Labs is to propose molecular designs, while MSD is responsible for taking any resulting products through later stages.
Who handles development and commercialization
MSD is reported to be responsible for preclinical and clinical development, manufacturing, and commercialization of any products that result. The reported compensation includes an upfront payment, possible milestone payments, and tiered royalties on net sales. Isomorphic Labs may elect to co-fund development in exchange for higher royalties, according to MarketScreener.